Role of Molecular Agents and Targeted Therapy in Clinical Trials for Women With Ovarian Cancer

JA Ledermann; C Marth; MS Carey; M Birrer; DDL Bowtell; S Kaye; I McNeish; A Oza; G Scambia; G Rustin; FB Stehman; D Gershenson; Giju Thomas; Els Berns; A Casado; N Ottevanger; F Hilpert; BG Kim; A Okamoto; M Bacon; H Kitchener; GCE Stuart

doi:10.1097/IGC.0b013e31821b2669

Role of Molecular Agents and Targeted Therapy in Clinical Trials for Women With Ovarian Cancer

JA Ledermann, C Marth, MS Carey, M Birrer, DDL Bowtell, S Kaye, I McNeish, A Oza, G Scambia, G Rustin, FB Stehman, D Gershenson, Giju Thomas, Els Berns, A Casado, N Ottevanger, F Hilpert, BG Kim, A Okamoto, M BaconH Kitchener, GCE Stuart

Research output: Contribution to journal › Article › Academic › peer-review

26 Citations (Scopus)

Abstract

There is now a greater understanding of the molecular pathways in ovarian cancer, and using this knowledge, a large number of new therapeutic agents can be tested. The success of these drugs will depend on selecting drugs that target known key dysfunctional molecular pathways. To make best use of these compounds, prognostic and predictive biomarkers need to be identified. Novel methods of assessment such as functional imaging need to be developed as additional biological end points to evaluate these therapies. Promising antitumor activity has been observed with some drugs, and careful consideration is needed to determine in what circumstances new agents, such as anti-angiogenic compounds, could be considered as a standard therapy. These areas were discussed at the 4th Ovarian Cancer Consensus Conference.

Original language	Undefined/Unknown
Pages (from-to)	763-770
Number of pages	8
Journal	International Journal of Gynecological Cancer
Volume	21
Issue number	4
DOIs	https://doi.org/10.1097/IGC.0b013e31821b2669
Publication status	Published - 2011

Research programs

EMC MM-03-86-01

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/IGC.0b013e31821b2669

Cite this

Ledermann, JA., Marth, C., Carey, MS., Birrer, M., Bowtell, DDL., Kaye, S., McNeish, I., Oza, A., Scambia, G., Rustin, G., Stehman, FB., Gershenson, D., Thomas, G., Berns, E., Casado, A., Ottevanger, N., Hilpert, F., Kim, BG., Okamoto, A., ... Stuart, GCE. (2011). Role of Molecular Agents and Targeted Therapy in Clinical Trials for Women With Ovarian Cancer. International Journal of Gynecological Cancer, 21(4), 763-770. https://doi.org/10.1097/IGC.0b013e31821b2669

@article{6400edb932d74dce82ff31d3b4275545,

title = "Role of Molecular Agents and Targeted Therapy in Clinical Trials for Women With Ovarian Cancer",

abstract = "There is now a greater understanding of the molecular pathways in ovarian cancer, and using this knowledge, a large number of new therapeutic agents can be tested. The success of these drugs will depend on selecting drugs that target known key dysfunctional molecular pathways. To make best use of these compounds, prognostic and predictive biomarkers need to be identified. Novel methods of assessment such as functional imaging need to be developed as additional biological end points to evaluate these therapies. Promising antitumor activity has been observed with some drugs, and careful consideration is needed to determine in what circumstances new agents, such as anti-angiogenic compounds, could be considered as a standard therapy. These areas were discussed at the 4th Ovarian Cancer Consensus Conference.",

author = "JA Ledermann and C Marth and MS Carey and M Birrer and DDL Bowtell and S Kaye and I McNeish and A Oza and G Scambia and G Rustin and FB Stehman and D Gershenson and Giju Thomas and Els Berns and A Casado and N Ottevanger and F Hilpert and BG Kim and A Okamoto and M Bacon and H Kitchener and GCE Stuart",

year = "2011",

doi = "10.1097/IGC.0b013e31821b2669",

language = "Undefined/Unknown",

volume = "21",

pages = "763--770",

journal = "International Journal of Gynecological Cancer",

issn = "1048-891X",

publisher = "BMJ Publishing Group",

number = "4",

}

Ledermann, JA, Marth, C, Carey, MS, Birrer, M, Bowtell, DDL, Kaye, S, McNeish, I, Oza, A, Scambia, G, Rustin, G, Stehman, FB, Gershenson, D, Thomas, G, Berns, E, Casado, A, Ottevanger, N, Hilpert, F, Kim, BG, Okamoto, A, Bacon, M, Kitchener, H & Stuart, GCE 2011, 'Role of Molecular Agents and Targeted Therapy in Clinical Trials for Women With Ovarian Cancer', International Journal of Gynecological Cancer, vol. 21, no. 4, pp. 763-770. https://doi.org/10.1097/IGC.0b013e31821b2669

TY - JOUR

T1 - Role of Molecular Agents and Targeted Therapy in Clinical Trials for Women With Ovarian Cancer

AU - Ledermann, JA

AU - Marth, C

AU - Carey, MS

AU - Birrer, M

AU - Bowtell, DDL

AU - Kaye, S

AU - McNeish, I

AU - Oza, A

AU - Scambia, G

AU - Rustin, G

AU - Stehman, FB

AU - Gershenson, D

AU - Thomas, Giju

AU - Berns, Els

AU - Casado, A

AU - Ottevanger, N

AU - Hilpert, F

AU - Kim, BG

AU - Okamoto, A

AU - Bacon, M

AU - Kitchener, H

AU - Stuart, GCE

PY - 2011

Y1 - 2011

N2 - There is now a greater understanding of the molecular pathways in ovarian cancer, and using this knowledge, a large number of new therapeutic agents can be tested. The success of these drugs will depend on selecting drugs that target known key dysfunctional molecular pathways. To make best use of these compounds, prognostic and predictive biomarkers need to be identified. Novel methods of assessment such as functional imaging need to be developed as additional biological end points to evaluate these therapies. Promising antitumor activity has been observed with some drugs, and careful consideration is needed to determine in what circumstances new agents, such as anti-angiogenic compounds, could be considered as a standard therapy. These areas were discussed at the 4th Ovarian Cancer Consensus Conference.

AB - There is now a greater understanding of the molecular pathways in ovarian cancer, and using this knowledge, a large number of new therapeutic agents can be tested. The success of these drugs will depend on selecting drugs that target known key dysfunctional molecular pathways. To make best use of these compounds, prognostic and predictive biomarkers need to be identified. Novel methods of assessment such as functional imaging need to be developed as additional biological end points to evaluate these therapies. Promising antitumor activity has been observed with some drugs, and careful consideration is needed to determine in what circumstances new agents, such as anti-angiogenic compounds, could be considered as a standard therapy. These areas were discussed at the 4th Ovarian Cancer Consensus Conference.

U2 - 10.1097/IGC.0b013e31821b2669

DO - 10.1097/IGC.0b013e31821b2669

M3 - Article

C2 - 21543938

SN - 1048-891X

VL - 21

SP - 763

EP - 770

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

IS - 4

ER -